UY27816A1 - NEW COMBINATION - Google Patents
NEW COMBINATIONInfo
- Publication number
- UY27816A1 UY27816A1 UY27816A UY27816A UY27816A1 UY 27816 A1 UY27816 A1 UY 27816A1 UY 27816 A UY27816 A UY 27816A UY 27816 A UY27816 A UY 27816A UY 27816 A1 UY27816 A1 UY 27816A1
- Authority
- UY
- Uruguay
- Prior art keywords
- new combination
- inhibitor
- pde5
- cgmp
- ace
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las combinaciones que comprenden a) un inhibidor de fosfodiesterasa de tipo 5 (PDE5) específica de monofosfato de guanosina c´clico (GMPc) y b) un inhibidor de enzima de conversión de angiotensina (ACE) son útiles para tratar la hipertensión.Combinations comprising a) a cyclic guanosine monophosphate type 5 (PDE5) phosphodiesterase inhibitor (cGMP) and b) an angiotensin conversion enzyme (ACE) inhibitor are useful for treating hypertension.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0211919A GB0211919D0 (en) | 2002-05-23 | 2002-05-23 | Novel combination |
GB0229784A GB0229784D0 (en) | 2002-12-20 | 2002-12-20 | Novel combination |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27816A1 true UY27816A1 (en) | 2003-12-31 |
Family
ID=29585817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27816A UY27816A1 (en) | 2002-05-23 | 2003-05-21 | NEW COMBINATION |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1506015A2 (en) |
JP (1) | JP2005529927A (en) |
KR (1) | KR20050004195A (en) |
CN (1) | CN1655820A (en) |
AR (1) | AR040090A1 (en) |
AU (1) | AU2003223071A1 (en) |
BR (1) | BR0311191A (en) |
CA (1) | CA2485984A1 (en) |
IL (1) | IL164975A0 (en) |
MX (1) | MXPA04010951A (en) |
NO (1) | NO20045517L (en) |
PA (1) | PA8574201A1 (en) |
PE (1) | PE20040514A1 (en) |
PL (1) | PL374198A1 (en) |
RU (1) | RU2004133973A (en) |
TW (1) | TW200407153A (en) |
UY (1) | UY27816A1 (en) |
WO (1) | WO2003099194A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
DE102004011512B4 (en) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical preparation containing pimobendan |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
FR2902009B1 (en) * | 2006-06-13 | 2012-12-07 | Bioprojet Soc Civ | USE OF A VASOPEPTIDASE INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
BRPI0716571A2 (en) * | 2006-08-24 | 2013-11-05 | Surface Logix Inc | PHARMACEUTICALLY OPTIMIZED COMPOUNDS |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
CN105377235A (en) | 2013-07-19 | 2016-03-02 | 勃林格殷格翰动物保健有限公司 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
CA3176466A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB2346877B (en) * | 1997-11-12 | 2001-12-05 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
TR200200954T2 (en) * | 1999-10-11 | 2002-09-23 | Pfizer Inc. | As phosphodiesterase inhibitors 5- (2-substituted-5-heterocyclylsulfonylpyrid-3-yl) - dihydropyrazolo [4,3-D] pyrimidine-7-they. |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
-
2003
- 2003-05-09 MX MXPA04010951A patent/MXPA04010951A/en unknown
- 2003-05-09 JP JP2004506721A patent/JP2005529927A/en not_active Abandoned
- 2003-05-09 RU RU2004133973/15A patent/RU2004133973A/en not_active Application Discontinuation
- 2003-05-09 WO PCT/IB2003/001889 patent/WO2003099194A2/en not_active Application Discontinuation
- 2003-05-09 EP EP03719042A patent/EP1506015A2/en not_active Withdrawn
- 2003-05-09 KR KR10-2004-7018868A patent/KR20050004195A/en active IP Right Grant
- 2003-05-09 BR BR0311191-1A patent/BR0311191A/en not_active IP Right Cessation
- 2003-05-09 CN CNA038118262A patent/CN1655820A/en active Pending
- 2003-05-09 PL PL03374198A patent/PL374198A1/en not_active Application Discontinuation
- 2003-05-09 AU AU2003223071A patent/AU2003223071A1/en not_active Abandoned
- 2003-05-09 CA CA002485984A patent/CA2485984A1/en not_active Abandoned
- 2003-05-12 TW TW092112826A patent/TW200407153A/en unknown
- 2003-05-19 PE PE2003000482A patent/PE20040514A1/en not_active Application Discontinuation
- 2003-05-21 AR ARP030101762A patent/AR040090A1/en unknown
- 2003-05-21 UY UY27816A patent/UY27816A1/en not_active Application Discontinuation
- 2003-05-22 PA PA20038574201A patent/PA8574201A1/en unknown
-
2004
- 2004-11-01 IL IL16497504A patent/IL164975A0/en unknown
- 2004-12-17 NO NO20045517A patent/NO20045517L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200407153A (en) | 2004-05-16 |
BR0311191A (en) | 2005-03-01 |
NO20045517L (en) | 2004-12-17 |
CN1655820A (en) | 2005-08-17 |
JP2005529927A (en) | 2005-10-06 |
WO2003099194A2 (en) | 2003-12-04 |
PL374198A1 (en) | 2005-10-03 |
MXPA04010951A (en) | 2005-06-08 |
KR20050004195A (en) | 2005-01-12 |
CA2485984A1 (en) | 2003-12-04 |
AU2003223071A1 (en) | 2003-12-12 |
PE20040514A1 (en) | 2004-08-24 |
RU2004133973A (en) | 2005-09-10 |
WO2003099194A3 (en) | 2004-06-03 |
EP1506015A2 (en) | 2005-02-16 |
PA8574201A1 (en) | 2003-12-19 |
IL164975A0 (en) | 2005-12-18 |
AR040090A1 (en) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105390T1 (en) | THERAPEUTIC MANAGEMENT OF PULMONARY HYPERTENSION | |
UY27816A1 (en) | NEW COMBINATION | |
ECSP056173A (en) | COMPOSITION THAT INCLUDES A PDE4 INHIBITOR AND A PDE5 INHIBITOR | |
ECSP034519A (en) | XANTINA PHOSPHODIESTERASE V INHIBITORS | |
DK1073658T3 (en) | Pyrazolopyrimidinone cGMP PDE5 Inhibitors for the Treatment of Sexual Disorder | |
DK1440709T3 (en) | Combinations comprising cGMP PDE5 inhibitors | |
IS6689A (en) | Phosphonate-nucleotide analogues and methods used to select and create them | |
NO20050400L (en) | New combination preparation | |
DE60323417D1 (en) | Gas turbine combustion chamber | |
NO20001583D0 (en) | Stimulation of hematopoietic cells in vitro | |
DK1268480T3 (en) | 8-Quinoline xanthine and 8-isoquinoline xanthine derivatives as PDE5 inhibitors | |
DE60134692D1 (en) | Lighting arrangement for keyboards and the dynamic or individual illumination of the keys and methods for their use | |
UY27729A1 (en) | QUINASE INHIBITORS. | |
HN2003000285A (en) | NEW ESPIROCONDENSED QUINAZOLINONES AND ITS USE AS PHOSPHODIESTERASE INHIBITORS | |
ATE234091T1 (en) | THROMBIN INHIBITORS | |
BR0314196A (en) | Tgf-beta inhibitors | |
GT200300231A (en) | HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | |
MXPA05006368A (en) | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2. | |
AR030718A1 (en) | BACILLUS THURINGIENSIS PROTEINS INHIBITING INSULTS FUSIONS AND METHODS OF USE OF THE SAME | |
DK1285065T3 (en) | Constructed proteins that fluoresce at long wavelengths | |
DOP2003000645A (en) | NEW COMBINATION | |
GB0000561D0 (en) | Treatment of diabetic ulcers | |
PA8477601A1 (en) | FKBP INHIBITORS | |
DE60136573D1 (en) | GEWEBEFIXATIVZUSAMMENSETZUNG | |
DOP2003000649A (en) | NEW COMBINATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150520 |